Brief Description
Avista Therapeutics develops innovative gene therapies for retinal diseases, including rare ophthalmic conditions that have a profound impact on quality of life. The company leverage a computationally guided scAAVengr platform to generate and validate a toolkit of proprietary AAV vectors. A quantitative, in vivo-based approach and clinical ophthalmology expertise allows Avista Therapeutics to rapidly translate new gene therapies to the clinic.
Inventors
Stephen Graf Brohawn, Hillel Adesnik, Madeline McCloud
Company Founders
Leah Byrne (UC Berkeley PhD, 2007, Neuroscience, postdoc, Helen Wills Neuroscience Institute), Paul Sieving, José-Alain Sahel
Timeline
- 2021. Company founded